Emerging therapies for Hypothalamic Obesity, including LB54640 and others, are anticipated to drive significant growth in the Hypothalamic Obesity market in the coming years.
DelveInsight has launched a new report on “Hypothalamic Obesity – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Hypothalamic Obesity, historical and forecasted epidemiology as well as the Hypothalamic Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Request for a detailed sample report @ https://www.delveinsight.com/report-store/hypothalamic-obesity-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Some of the key facts of the Hypothalamic Obesity Market Report:
-
Hypothalamic obesity is a complex disorder typically caused by damage to the hypothalamus due to brain tumors, surgery, radiation, head trauma, or genetic abnormalities. Studies estimate that the annual incidence of tumor- or treatment-related hypothalamic obesity (TTR-HO) in Germany ranges from 0.7 to 1.7 cases per million people.
-
Common symptoms include excessive hunger, an inability to feel full, rapid weight gain, daytime sleepiness, disrupted circadian rhythms, and dysregulation of thirst, body temperature, heart rate, and blood pressure.
-
Conventional treatment strategies focus on calorie-restricted diets, exercise, and pharmacotherapy, though no fully effective treatment exists. Pharmacological approaches target alterations in efferent pathways, often using off-label therapies such as sympathomimetic appetite suppressants, leptin-sensitizing agents, hormone replacement therapy, stimulants, and GLP-1 agonists.
-
Recent advances offer promising developments. In January 2024, Rhythm Pharmaceuticals completed patient screening for a pivotal Phase III trial evaluating setmelanotide in individuals with acquired hypothalamic obesity. Enrollment exceeded expectations, with over 140 patients actively screened and undergoing baseline assessments.
-
In the same month, Rhythm Pharmaceuticals also entered a global licensing agreement with LG Chem for LB54640, an investigational oral MC4R agonist in Phase II trials, reflecting increasing pharmaceutical efforts to address hypothalamic obesity.
-
Despite these advances, there remains a critical need for further clinical research to manage the growing prevalence of hypothalamic obesity effectively.
-
Key companies such as Rhythm Pharmaceuticals and others are actively developing new therapies to improve the treatment landscape. Promising pipeline candidates in various stages include LB54640, IMCIVREE, and others.
-
In March 2025, Rhythm Pharmaceuticals announced that the U.S. FDA awarded Breakthrough Therapy Designation to setmelanotide for the treatment of hypothalamic obesity. This designation is designed to accelerate the development and review of therapies that show significant improvements over existing treatments for serious or life-threatening conditions.
-
During the same month, Japan’s Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation to setmelanotide for acquired hypothalamic obesity, supporting the drug’s development and regulatory approval for this rare condition.
Key benefits of the Hypothalamic Obesity market report:
-
Hypothalamic Obesity market report covers a descriptive overview and comprehensive insight of the Hypothalamic Obesity Epidemiology and Hypothalamic Obesity market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
-
The Hypothalamic Obesity market report provides insights on the current and emerging therapies.
-
Hypothalamic Obesity market report provides a global historical and forecasted market covering drug outreach in 7MM.
-
The Hypothalamic Obesity market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hypothalamic Obesity market.
Got queries? Click here to know more about the Hypothalamic Obesity Market Landscape
Hypothalamic Obesity Overview
Hypothalamic obesity is a rare condition caused by damage to the hypothalamus, the brain region that regulates hunger and metabolism. Such damage can result from tumors (e.g., craniopharyngiomas), brain injuries, or surgical interventions, disrupting appetite control and energy balance. This leads to uncontrolled weight gain, reduced energy expenditure, and a poor response to conventional weight-loss methods.
To know more about hypothalamic obesity, treatment options, visit: https://www.delveinsight.com/report-store/hypothalamic-obesity-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Hypothalamic Obesity Market Outlook
Leading companies such as LG Chem and Rhythm Pharmaceuticals are progressing their drug candidates through various stages of clinical development to investigate potential treatments for hypothalamic obesity.
This analysis offers a detailed overview of the hypothalamic obesity market, examining both approved therapies and late-stage pipeline candidates. It assesses their impact considering factors such as annual treatment costs, inclusion/exclusion criteria, mechanisms of action, patient adherence, market demand, growing patient populations, target demographics, expected launch timelines, competition with existing treatments, brand positioning, market influence, and insights from key opinion leaders.
Discover how the hypothalamic obesity market is rising in the upcoming years, click: https://www.delveinsight.com/sample-request/hypothalamic-obesity-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Hypothalamic Obesity Emerging Drugs
-
IMCIVREE (setmelanotide): Rhythm Pharmaceuticals
-
LB54640 (LR19021): LG Chem/ Rhythm Pharmaceuticals
Scope of the Hypothalamic Obesity Market Report
-
Study Period: 2020-2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Hypothalamic Obesity Companies: Rhythm Pharmaceuticals, and others
-
Key Hypothalamic Obesity Therapies: IMCIVREE, LB54640, and others
-
Hypothalamic Obesity Therapeutic Assessment: Hypothalamic Obesity current marketed and Hypothalamic Obesity emerging therapies
-
Hypothalamic Obesity Market Dynamics: Hypothalamic Obesity market drivers and Hypothalamic Obesity market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Hypothalamic Obesity Unmet Needs, KOL’s views, Analyst’s views, Hypothalamic Obesity Market Access and Reimbursement
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Hypothalamic Obesity Patient Share (%) Overview at a Glance
5. Hypothalamic Obesity Market Overview at a Glance
6. Hypothalamic Obesity Disease Background and Overview
7. Hypothalamic Obesity Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypothalamic Obesity
9. Hypothalamic Obesity Current Treatment and Medical Practices
10. Unmet Needs
11. Hypothalamic Obesity Emerging Therapies
12. Hypothalamic Obesity Market Outlook
13. Country-Wise Hypothalamic Obesity Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Hypothalamic Obesity Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Hypothalamic Obesity Market Outlook 2034
Related Reports:
Hypothalamic Obesity Pipeline Insights, DelveInsight
“Hypothalamic Obesity Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hypothalamic Obesity market. A detailed picture of the Hypothalamic Obesity pipeline landscape is provided, which includes the disease overview and Hypothalamic Obesity treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/